I looked at a couple of failed Phase 2/3 trials and in general there was a 60% hit. They did bounce back somewhat over the subsequent weeks, if they had a pipeline. Unfortunately, the reverse split is a very likely scenario. Except for senior management and the BOD, we all suffer-investors, employees and patients. I will probably just put this investment in the back pocket and hope it recovers in the next year or two. Unless, we can find a partner.
For many of us, the only thing that was "astronomical" was our loss. Our timing was terrible to do a chemo combo trial. Within months, we knew even good results would not be the future of the company.
So sad for so many.
News 
Market Data 
Discover 
